Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97

Q: How many Entrada Therapeutics (TRDA) options did Gina Chapman receive?

Gina Chapman received stock options covering 19,000 shares of Entrada Therapeutics common stock. The filing also notes that, following this award, her total stock option holdings reported in this transaction amount to 19,000 derivative securities related to common shares.

Q: When do Gina Chapman’s Entrada Therapeutics (TRDA) options expire?

Gina Chapman’s stock options are scheduled to expire on June 10, 2036 . After this expiration date, any unexercised options will no longer be usable to purchase Entrada Therapeutics common stock, even if they have already vested.

Q: Is Gina Chapman’s Entrada Therapeutics (TRDA) option grant a market purchase or a compensation award?

The Form 4 classifies the transaction as a grant or award acquisition with a zero-dollar transaction price. This indicates the options were granted as compensation rather than bought on the open market, consistent with a director equity award.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Entrada Therapeutics director Gina Chapman received a grant of stock options to buy 19,000 shares of common stock at an exercise price of $5.97 per share. These options vest on the earlier of the one-year anniversary of June 10, 2026 or the company’s next annual meeting of stockholders and expire on June 10, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chapman Gina

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 19,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 19,000 options Exercise price: $5.97 per share Underlying shares: 19,000 shares +2 more

5 metrics

Options granted 19,000 options Stock Option (Right to Buy) granted on June 10, 2026

Exercise price $5.97 per share Conversion or exercise price for underlying common stock

Underlying shares 19,000 shares Underlying common stock for the option grant

Post-grant derivative holdings 19,000 derivative securities Total stock options following the transaction

Option expiration June 10, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), exercise price, derivative securities, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "5.9700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"derivativeTransactionCount: 1, derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 05:17 PM Accepted by SEC EDGAR 06/12/2026 - 05:16 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chapman Gina

(Last)

(First)

(Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON

MASSACHUSETTS

02210

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.97	06/10/2026		A		19,000		⁽¹⁾	06/10/2036	Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Entrada Therapeutics (TRDA) report for Gina Chapman?

Entrada Therapeutics reported that director Gina Chapman received a grant of stock options for 19,000 shares of common stock. These options give her the right to buy shares at a fixed exercise price, subject to vesting conditions and an expiration date.

How many Entrada Therapeutics (TRDA) options did Gina Chapman receive?

Gina Chapman received stock options covering 19,000 shares of Entrada Therapeutics common stock. The filing also notes that, following this award, her total stock option holdings reported in this transaction amount to 19,000 derivative securities related to common shares.

What is the exercise price of Gina Chapman’s Entrada Therapeutics (TRDA) options?

The stock options granted to Gina Chapman have an exercise price of $5.97 per share. This means she can buy Entrada Therapeutics common stock at $5.97 for each optioned share once the options vest and before they expire in 2036.

When do Gina Chapman’s Entrada Therapeutics (TRDA) options vest?

The options vest and become exercisable on the earlier of two dates: the one-year anniversary of June 10, 2026, or Entrada Therapeutics’ next annual meeting of stockholders. Vesting must occur before she can use the options to purchase common shares.

When do Gina Chapman’s Entrada Therapeutics (TRDA) options expire?

Gina Chapman’s stock options are scheduled to expire on June 10, 2036. After this expiration date, any unexercised options will no longer be usable to purchase Entrada Therapeutics common stock, even if they have already vested.

Is Gina Chapman’s Entrada Therapeutics (TRDA) option grant a market purchase or a compensation award?

The Form 4 classifies the transaction as a grant or award acquisition with a zero-dollar transaction price. This indicates the options were granted as compensation rather than bought on the open market, consistent with a director equity award.